A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose, Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability Study of CTP-499 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2016
At a glance
- Drugs CTP 499 (Primary) ; CTP 499 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; First in man
- Sponsors Concert Pharmaceuticals
- 01 Jul 2016 Results published in the Clinical Pharmacology in Drug Development.
- 19 Oct 2011 Results were presented at the American Society of Nephrology's (ASN) Kidney Week 2011, according to a Concert Pharmaceuticals media release.
- 22 Jun 2011 Status changed from recruiting to completed.